Latest & greatest articles for pantoprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pantoprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pantoprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pantoprazole

1. Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU.

Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU. BACKGROUND: Prophylaxis for gastrointestinal stress ulceration is frequently given to patients in the intensive care unit (ICU), but its risks and benefits are unclear. METHODS: In this European, multicenter, parallel-group, blinded trial, we randomly assigned adults who had been admitted to the ICU for an acute condition (i.e., an unplanned admission) and who were at risk for gastrointestinal bleeding to receive 40 mg (...) of intravenous pantoprazole (a proton-pump inhibitor) or placebo daily during the ICU stay. The primary outcome was death by 90 days after randomization. RESULTS: A total of 3298 patients were enrolled; 1645 were randomly assigned to the pantoprazole group and 1653 to the placebo group. Data on the primary outcome were available for 3282 patients (99.5%). At 90 days, 510 patients (31.1%) in the pantoprazole group and 499 (30.4%) in the placebo group had died (relative risk, 1.02; 95% confidence interval [CI

NEJM2018

2. Pantoprazole

Pantoprazole Top results for pantoprazole - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for pantoprazole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

3. Continuous versus Intermittent Intravenous Pantoprazole for Acute Gastrointestinal Bleeding

Continuous versus Intermittent Intravenous Pantoprazole for Acute Gastrointestinal Bleeding Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid (...) Intravenous Pantoprazole for Acute Gastrointestinal Bleeding: A Review of the Clinical Effectiveness and Guidelines DATE: 01 May 2015 CONTEXT AND POLICY ISSUES The gastrointestinal (GI) tract stretches from the mouth to the anus and gastrointestinal bleeding describes any bleeding that starts in the GI tract. Acute GI bleeding refers to the passage of a clinically significant amount of blood (i.e., the passage of more than a scant amount of blood) 1 Acute bleeding in the upper part of the GI tract often

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

4. Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding

Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding Wang J, Yang K, Ma B, Tian J, Liu Y, Bai Z, Jiang L, Sun S, Li J, Liu R, Hao X, He X CRD summary The authors concluded that intravenous pantoprazole (...) administered after endoscopic treatment reduces ulcer re-bleeding, surgical intervention, and length of hospital stay, but not mortality nor blood transfusions. This was a generally well-conducted review and the findings for the overall analyses are likely to be reliable. Authors' objectives To evaluate the effectiveness of intravenous pantoprazole as an additional treatment following successful endoscopic haemostasis of peptic ulcer bleeding. Searching The Cochrane Central Register of Controlled Trials

DARE.2009

5. Controloc Control - pantoprazole

Controloc Control - pantoprazole European Medicines Agency Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: mail@emea.europa.eu http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. London, 8 May 2009 Doc.Ref.: EMEA/374215/2009 ASSESSMENT REPORT FOR CONTROLOC Control International Nonproprietary Name: pantoprazole Procedure (...) of heartburn is universal and that it is in patients’ interest across the community to allow access to a harmonised non- prescription pantoprazole product. In addition, it would give Community-wide access and consumer protection, based on harmonised labelling and avoid diverted markets. The legal basis for this application refers to Article 10(3) of Directive 2001/83/EC, as amended – hybrid application. The chosen reference product is: Reference medicinal product which is or has been authorised

European Medicines Agency - EPARs2009

7. Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions

Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions Kaplan G G, Bates D, McDonald D, Panaccione R, Romagnuolo J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of an intravenous proton pump inhibitor (IV PPI), pantoprazole, in patients with upper gastrointestinal bleeding (UGIB) or patients receiving nil by mouth (NPO). In connection to this, the study examined the use of a multidisciplinary intervention to reduce inappropriate use of IV PPI. This intervention had four

NHS Economic Evaluation Database.2005

8. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing (...) and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Caro J J, Salas M, Ward A Authors' objectives To estimate the healing and relapse rates in the acute and maintenance treatment of gastroesophageal reflux disease (GERD) with the newer proton-pump inhibitors (PPIs) lansoprazole, rabeprazole and pantoprazole, compared

DARE.2001

9. Pantoprazole

Pantoprazole Pantoprazole Pantoprazole Poole P Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Poole P. Pantoprazole. University HealthSystem Consortium (UHC). Drug Monograph. 2000 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new and emerging pharmaceuticals. Monographs are written by drug

Health Technology Assessment (HTA) Database.2000